A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

A First-in-Human, Double-Blind, Randomised, Vehicle Controlled Phase I/II Proof of Concept Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04737304
• Other study ID #: BB-2293-101b
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 14, 2020
• Est. completion date: January 26, 2023

Study information

• Verified date: June 2023
• Source: BenevolentAI Bio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomised, adaptive design, double-blind, placebo-controlled, first-in-human, two-part study to investigate the safety, tolerability, PK and preliminary efficacy of multiple topical doses of BEN2293 in patients with mild to moderate AD.

Description:

This Protocol will be adaptive and designed to enable knowledge gained from the previous cohort to be applied to subsequent cohorts. Changes made will be within the boundaries of the adaptive elements with clear control mechanisms and guidance for staying within these boundaries.

Part A is a randomised, double-blind, placebo-controlled, sequential group study to investigate ascending multiple topical doses of BEN2293 in patients with mild to moderate AD. Patients will participate in only one cohort.

Part B is a randomised, double-blind, placebo-controlled, parallel group study to investigate up to two dose regimens of topical doses of BEN2293 administered for a maximum of 28 days in patients with mild to moderate AD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 123
• Est. completion date: January 26, 2023
• Est. primary completion date: January 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females with mild to moderate AD (based on vIGA) free from other clinically significant illness or disease that may adversely affect the safety of the patient or the integrity of the study as determined by medical history, physical examination, safety laboratory and other assessments.

• History of AD for at least 6 months diagnosed by a dermatologist or GP.

• Previous or current successful treatment with topical corticosteroids.

• A vIGA score of 2 (mild) to 3 (moderate) at both Screening and Day -1 (Part A) and at Screening, Day-3 and Day 1 (Part B).

Exclusion Criteria:

• Atopic dermatitis of such severity that the patient could not comply with the demands of the study and/or the patient is not a suitable candidate for a placebo controlled study, as per Investigator's discretion.

• Any skin tattoo, scar, cuts, bruises, or other skin damage, including excessive UV exposure, at the possible IMP application sites.

• Patients who have AD lesions affecting >3% untreatable areas (face, scalp, genitals, palms of hands or soles of feet).

• Have concomitant skin disease or infection (e.g., acne, impetigo) or presence of skin comorbidities in the study area to be dosed that may interfere with study assessments.

• Patients who are excessively hirsute in areas of skin to be dosed with study ointment.

• Patients who are unwilling to stop hair removal by any means (including shaving, waxing or depilatory creams) to skin areas to be dosed with study ointment for 2 weeks prior to Day -1 and throughout the duration of the study.

• Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations as judged by the Investigator (including [but not limited to], neurological, psychiatric, endocrine, cardiovascular, gastrointestinal, hepatic, or renal disorder).

• The patient has participated in a clinical study and has received a medication or a new chemical entity within 3 months prior to Day 1.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• BEN2293 (0.25% or 1.0% w/w) or matching placebo
BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.

Locations

Country	Name	City	State
United Kingdom	MAC Clinical Research	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
BenevolentAI Bio

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability assessed by means of incidence of adverse events, incidence of adverse events at the local application site, mean vital signs, mean 12-lead ECG parameters and mean safety laboratory results.	Parameters measured by prompted reporting of adverse events and scheduled safety assessments.	Up to 28 days
Secondary	PK-Cmax	The investigation of the plasma PK of BEN2293 and metabolite BEN6403 following multiple topical doses to mild to moderate AD patients.	Up to 28 days
Secondary	PK-Tmax	The investigation of the plasma PK of BEN2293 and metabolite BEN6403 following multiple topical doses to mild to moderate AD patients.	Up to 28 days
Secondary	PK-T1/2	The investigation of the plasma PK of BEN2293 and metabolite BEN6403 following multiple topical doses to mild to moderate AD patients.	Up to 28 days
Secondary	PK-AUC	The investigation of the plasma PK of BEN2293 and metabolite BEN6403 following multiple topical doses to mild to moderate AD patients.	Up to 28 days
Secondary	PK- over a dosing interval (AUC?)	The investigation of the plasma PK of BEN2293 and metabolite BEN6403 following multiple topical doses to mild to moderate AD patients.	Up to 28 days
Secondary	PK - Accumulation ratio	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients	Up to 28 days
Secondary	Time to itch reduction	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD.	Up to 28 days
Secondary	Fraction of patients achieving itch reduction	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD.	Up to 28 days
Secondary	Change from baseline in the Numerical Rating Scale (NRS) for pruritus - Worst Itch over 24 hours	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. Scale graded by 0 - no itch through to 10 - worst imaginable itch.	Up to 28 days
Secondary	Change from baseline in the Numerical Rating Scale (NRS) for pruritus - Current Itch	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. Scale graded by 0 - no itch through to 10 - worst imaginable itch.	Up to 28 days
Secondary	Change from baseline in Eczema Area and Severity Index (EASI) score	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. Index is graded 0 - none, absent, 1 - mild, 2 - moderate and 3 - severe.	Up to 28 days
Secondary	Number of patients achieving improvement in Eczema Area and Severity Index (EASI) score	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. Index is graded 0 - none, absent, 1 - mild, 2 - moderate and 3 - severe.	Up to 28 days
Secondary	Change from baseline in BSA affected by AD in treated area(s)	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD.	Up to 28 days
Secondary	Change from baseline in vIGA score	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD.	Up to 28 days
Secondary	Change from baseline in Patient Oriented Eczema Measure (POEM)	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. 7 questions based on skin condition graded between 0 - no days to 4 - everyday, with a total score of 28 being the worse.	Up to 28 days
Secondary	Change from baseline in Dermatology Life Quality Index (DLQI)	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. Index graded from 0 - not at all to 3 - very much. The higher the score, the more quality of life is impaired.	Up to 28 days
Secondary	Change from baseline in EQ5D score	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD.	Up to 28 days
Secondary	Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS)	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. System has questions based on Itch - Scratching Behaviour, Itch - Mood and Sleep and Itch - Interference. questions are graded from 1 - never to 5 - almost always (worse score).	Up to 28 days
Secondary	Change from baseline in Insomnia Severity Index (ISI)	The investigation of the effect of BEN2293 on pruritus and Atopic Dermatitis in patients with mild to moderate AD. 7 questions based on quality of sleep, graded 0 - none to 4 - very severe. Total score of 28 being the worse.	Up to 28 days